Becton, Dickinson and Company (BDX)
Stock Price Chart
Key Info
| Market Cap | 67.37B |
| Revenue (ttm) | 17.12B |
| Net Income (ttm) | 767.00M |
| Shares Out | 290.03M |
| EPS (ttm) | 2.71 |
| PE Ratio | 85.72 |
| Forward PE | 18.02 |
| Dividend | $3.32 |
| Dividend Yield | 1.43% |
Stock Quote
| Trading Day | November 30 |
| Last Price | $232.30 |
| Previous Close | $228.96 |
| Change ($) | 3.34 |
| Change (%) | 1.46% |
| Day's Open | 230.08 |
| Day's Range | 229.97 - 234.04 |
| Day's Volume | 1,114,435 |
| 52-Week Range | 199.25 - 283.16 |
More Stats
| Market Cap | 67.37B |
| Enterprise Value | 82.37B |
| Earnings Date (est) | n/a |
| Ex-Dividend Date | Sep 8, 2020 |
| Shares Outstanding | 290.03M |
| Float | n/a |
| EPS (basic) | 2.75 |
| EPS (diluted) | 2.71 |
| FCF / Share | 9.42 |
| Dividend | $3.32 |
| Dividend Yield | 1.43% |
| Earnings Yield | 1.17% |
| FCF Yield | 4.05% |
| Payout Ratio | 114.90% |
| Shares Short | 2.00M |
| Short Ratio | 1.56 |
| Short % of Float | n/a |
| Beta | 0.85 |
| PE Ratio | 85.72 |
| Forward PE | 18.02 |
| P/FCF Ratio | 24.69 |
| PS Ratio | 3.94 |
| PB Ratio | 2.77 |
| Revenue | 17.12B |
| Operating Income | 1.48B |
| Net Income | 767.00M |
| Free Cash Flow | 2.73B |
| Net Cash | -14.99B |
| Net Cash / Share | -51.70 |
| Gross Margin | 46.26% |
| Operating Margin | 8.67% |
| Profit Margin | 4.50% |
| FCF Margin | 15.94% |
| ROA | 2.98% |
| ROE | 3.90% |
| ROIC | 5.90% |
Analyst Forecasts
Analyst Consensus: Buy
Financial Performance
Financial Overview
| Year | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 17,117 | 17,290 | 15,983 | 12,093 | 12,483 | 10,282 | 8,446 | 8,054 | 7,708 | 7,584 |
| Revenue Growth | -1% | 8.18% | 32.17% | -3.12% | 21.41% | 21.74% | 4.87% | 4.49% | 1.64% | - |
| Gross Profit | 7,577 | 8,288 | 7,269 | 5,965 | 5,991 | 4,695 | 4,301 | 4,171 | 3,953 | 3,959 |
| Operating Income | 1,484 | 1,760 | 1,509 | 1,522 | 1,430 | 1,074 | 1,606 | 1,255 | 1,558 | 1,665 |
| Net Income | 874 | 1,234 | 311 | 1,100 | 976 | 695 | 1,185 | 1,293 | 1,170 | 1,271 |
| Shares Outstanding | 290 | 270 | 268 | 228 | 213 | 210 | 192 | 194 | 200 | 217 |
| Earnings Per Share | 2.71 | 3.94 | 0.60 | 4.60 | 4.49 | 3.35 | 5.99 | 6.49 | 5.59 | 5.62 |
| EPS Growth | -31.22% | 556.67% | -86.96% | 2.45% | 34.03% | -44.07% | -7.7% | 16.1% | -0.53% | - |
| Dividend Per Share | 3.16 | 3.08 | 3.00 | 2.92 | 2.64 | 2.40 | 2.18 | 1.98 | 1.80 | 1.64 |
| Dividend Growth | 2.6% | 2.67% | 2.74% | 10.61% | 10% | 10.09% | 10.1% | 10% | 9.76% | - |
| Operating Cash Flow | 3,539 | 3,330 | 2,865 | 2,550 | 2,559 | 1,730 | 1,746 | 1,717 | 1,760 | 1,716 |
| Capital Expenditures | -810 | -957 | -895 | -727 | -693 | -596 | -653 | -588 | -553 | -599 |
| Free Cash Flow | 2,729 | 2,373 | 1,970 | 1,823 | 1,866 | 1,134 | 1,093 | 1,129 | 1,207 | 1,117 |
| Cash & Equivalents | 2,937 | 620 | 1,253 | 14,200 | 1,907 | 1,519 | 2,750 | 2,608 | 2,181 | 1,563 |
| Total Debt | 17,931 | 19,390 | 21,495 | 18,870 | 11,551 | 12,822 | 3,971 | 3,970 | 4,166 | 2,720 |
| Net Cash / Debt | -14,994 | -18,770 | -20,242 | -4,670 | -9,644 | -11,303 | -1,221 | -1,362 | -1,985 | -1,156 |
| Assets | 54,012 | 51,765 | 53,904 | 37,734 | 25,586 | 26,478 | 12,447 | 12,149 | 11,361 | 10,430 |
| Liabilities | 30,247 | 30,684 | 32,910 | 24,786 | 17,953 | 19,314 | 7,394 | 7,106 | 7,225 | 5,602 |
| Book Value | 23,765 | 21,081 | 20,994 | 12,948 | 7,633 | 7,164 | 5,053 | 5,043 | 4,136 | 4,828 |
Company Profile
Company Details
| Full Name | Becton, Dickinson and Company |
| Country | United States |
| Employees | 72,000 |
| CEO | Thomas E. Polen |
Stock Information
| Ticker Symbol | BDX |
| Stock Exchange | New York Stock Exchange |
| Sector | Healthcare |
| Industry | Medical Instruments & Supplies |
| Unique Identifier | NYSE: BDX |
| IPO Date | April 23, 1962 |
Description
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps, dedicated disposables, IV fluids, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products and systems; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for high-throughput single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. Becton, Dickinson and Company was founded in 1897 and is based in Franklin Lakes, New Jersey.